Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IO vs IV Vancomycin and Cefazolin in TKA
NCT06640491Phase 2Recruiting
- Sponsor
- Houston Methodist Research Institute
- Start
- May 2025
- Primary completion
- Dec 2030
- Modality
- Reversible Covalent Inhibitors, Cyclic Peptides, Antimicrobial Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of vancomycin, cefazolin in surgical site infection (SSI), sponsored by Houston Methodist Research Institute. Started May 2025; status: recruiting.
02
Drugs
vancomycincefazolin
03
Conditions
surgical site infection (SSI)
Beyond the preview
Go deeper on NCT06640491.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06640491.